氨磺必利与利培酮治疗晚发性精神分裂症的疗效和安全性比较  

Comparison of efficacy and safety between amisulpride and risperidone in the treatment of late-onset schizophrenia

作　　者：张东卫[1] ZHANG Dongwei(Department of Psychosomatic Medicine,the Second Affiliated Hospital of Xinxiang Medical University,Xinxiang 453002,Henan Province,China)

机构地区：[1]新乡医学院第二附属医院心身医学科,河南新乡453002

出　　处：《新乡医学院学报》2023年第6期534-537,共4页Journal of Xinxiang Medical University

摘　　要：目的 比较氨磺必利与利培酮治疗晚发性精神分裂症的疗效和安全性。方法 选择2018年3月至2019年9月新乡医学院第二附属医院收治的62例晚发性精神分裂症患者为研究对象。根据治疗方法将患者分为氨磺必利组(n=32)和利培酮组(n=30)。氨磺必利组患者给予氨磺必利治疗,起始剂量为50 mg·d^(-1),分2次口服,依照病情变化1周内逐渐增加至治疗剂量,治疗剂量范围为100~800 mg·d^(-1);利培酮组患者给予利培酮治疗,起始剂量为1 mg·d^(-1),分2次口服,1周内逐渐增加至治疗剂量,治疗剂量范围为2~5 mg·d^(-1)。2组患者均连续治疗6周。治疗前和治疗6周时,采用阳性和阴性症状量表(PANSS)评估2组患者的精神症状严重程度和临床疗效,并计算治疗总有效率。采用治疗伴发症状量表(TESS)评估2组患者的不良反应程度。观察并记录2组患者不良反应发生情况,并计算不良反应总发生率。结果 氨磺必利组和利培酮组患者的治疗总有效率分别为96.87%(31/32)、96.67%(29/30);2组患者的治疗总有效率比较差异无统计学意义(χ^(2)=0.122,P>0.05)。治疗前及治疗6周时,2组患者的PANSS评分比较差异无统计学意义(P>0.05);氨磺必利组和利培酮组患者治疗6周时的PANSS评分均显著低于治疗前(P<0.05)。治疗6周时,氨磺必利组患者的TESS评分显著低于利培酮组(P<0.05)。氨磺必利组患者的体质量增加、催乳素升高、急性肌张力障碍、静坐不能发生率显著低于利培酮组(χ^(2)=31.270、29.650、3.687,P<0.05)。2组患者的心电图QTc间期延长、肝功能异常发生率比较差异无统计学意义(χ^(2)=1.071、0.879,P>0.05)。结论 氨磺必利与利培酮治疗晚发性精神分裂症患者的临床效果相当,采用氨磺必利治疗的患者体质量增加、催乳素升高及急性肌张力障碍、静坐不能等不良反应较少。Objective To compare the efficacy and safety of amisulpride and risperidone in the treatment of late-onset schizophrenia.Methods A total of 62 patients with late onset schizophrenia admitted to the Second Affiliated Hospital of Xinxiang Medical University from March 2018 to September 2019 were selected as the study subjects.According to the treatment method,the patients were divided into the amisulpride group(n=32)and the risperidone group(n=30).The patients in the amisulpride group were treated with amisulpride at an initial dose of 50 mg·d^(-1),taken orally in two doses,gradually increasing to the treatment dose within a week according to changes in the condition,with a treatment dose range of 100-800 mg·d^(-1);the patients in the risperidone group were treated with risperidone at an initial dose of 1 mg·d^(-1),administered orally in two doses,gradually increasing to the treatment dose within a week,with a treatment dose range of 2-5 mg·d^(-1).The patients in the two groups were treated continuously for 6 weeks.Before treatment and at 6 weeks of treatment,the severity of mental symptoms and clinical efficacy of patients in the two groups were evaluated by the positive and negative symptoms scale(PANSS),and the total effective of treatment was calculated.The degree of adverse reactions of patients in the two groups was evaluated by the treatment emergent symptom scale(TESS).The occurrence of adverse reactions of patients in the two groups was observed and recorded,and the total incidence rate of adverse reactions was calculated.Results The total effective rates of patients in the amisulpride group and the risperidone group were 96.87%(31/32)and 96.67%(29/30),respectively;there was no significant difference in the total effective rate of patients between the two groups(χ^(2)=0.122,P>0.05).There was no significant difference in PANSS scores of patients between the two groups before treatment and at 6 weeks of treatment(P>0.05);the PANSS scores of patients in the amisulpride group and risperidone group at 6 we

关 键 词：氨磺必利 利培酮 精神分裂症 阳性和阴性症状量表 

分 类 号：R749.3[医药卫生—神经病学与精神病学]